|
시장보고서
상품코드
1193268
육종 치료제 시장 : 적응 질환별, 치료법별, 최종 사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)Sarcoma Drugs Market By Disease Indication, By Treatment, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031 |
||||||
육종 치료제의 세계 시장은 2021년에 11억 2700만 달러, 2031년에는 24억 9710만 달러에 이르며 2022년부터 2031년에 걸쳐 CAGR 8.3%로 성장할 것으로 예측되고 있습니다.
육종은 연골, 지방, 근육, 혈관, 섬유 조직 등의 결합 조직이나 지지 조직 등의 연부 조직이나 뼈에 발생하는 암의 일종입니다. 육종은 암이 발생하는 부위에 따라 다양한 종류가 있습니다. 예를 들어, 횡문근육종은 근육으로, 지방육종은 지방으로, 골육종은 뼈에서 발생합니다. 암의 종류와 악성도에 따라 치료 방침이나 예후(현미경으로 보았을 때의 암의 이상 정도, 암의 증식이나 전이의 속도)가 결정됩니다. 육종은 어린이와 성인 모두 발병 할 수 있습니다. 육종의 치료에는 화학 요법과 표적 치료의 두 가지 치료법이 있습니다.
육종 치료제 시장은 암 유병률의 증가, 육종 치료제의 개발에 있어서의 기술적 진보, 육종 치료제의 제품 상시 및 승인의 수의 증가에 의해 견인되고 있습니다. 예를 들어 세계암 연구기금 인터내셔널에 따르면 전 세계에서 18,094,716명의 암 환자가 진단되었다고 보고되었습니다. 또한 연부 육종의 유병률 증가는 치료 목적으로 육종 치료제의 수요를 촉진하고 있습니다. 따라서 이 요인은 육종 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 암 협회에 따르면, 2022년에는 미국에서 새롭게 약 13,190개의 연부 육종이 진단되고, 그 중 남성에서 7,590, 여성에서 5,600으로 추정된다. 또한 이 출처에 따르면 연부육종으로 사망하는 것은 약 5,130명(남성 2,740명, 여성 2,390명)으로 추정되고 있습니다.
세계의 육종 치료제 시장은 연부 육종과 싸우는 환자의 증가로 인해 수술 치료보다 약물 치료로 소비자의 선호의 변화가 증가하고 발전할 것으로 예측됩니다. 화학요법 및 표적 치료의 사용은 치유 속도, 이환율 및 사망률의 낮음, 입원 기간의 단축 등 많은 이점에 의해 지원됩니다.
노년 인구가 암 등의 만성 질환에 걸리기 쉬워지고 있습니다. 노년 인구의 증가는 암 치료용 육종 치료제의 수요를 증가시킵니다. 이러한 요인은 육종 치료제 시장의 성장에 기여합니다. 또한 세계 각국의 정부는 건강 관리 분야에 대한 지출을 늘리고 있습니다. 예를 들어, Medicare & Medicaid Service Center에 따르면 미국 의료비는 2019년부터 2020년까지 9.7% 성장하여 4조 1,000억 달러(1인당 12,530달러)에 이르렀습니다. 마찬가지로 국가 통계국의 발표에 따르면 영국의 의료비 총액은 2019년 국내총생산(GDP)의 10.2%에 비해 2020년에는 12.8%를 차지하게 되었다. 게다가 건강 관리 지출의 약 30%는 의료 인프라, 특히 공중 보건 센터(병원)에서 사용되는 의료 기기를 업그레이드하는 데 사용되는 것으로 추정됩니다. 따라서 이러한 세계 건강 관리 지출의 증가는 다양한 질병 치료에서 육종 치료제의 수요를 촉진하고 시장 성장을 밀어 올릴 것으로 예상됩니다.
한편, 육종 치료제와 관련된 높은 비용과 화학 요법의 부작용은 시장 성장을 방해합니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 개요
- 시장의 정의와 범위
- 주요 조사 결과
- 주요 투자 포켓
- Porter's Five Forces 분석
- 주요 기업의 포지셔닝
- 시장 역학
- 촉진 요인
- 억제 요인
- 기회
- COVID-19 영향 분석
제4장 육종 치료제 시장 : 적응 질환별
- 개요
- 시장 규모 및 예측
- 악성골 종양
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
- 연부조직육종
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
- 연부육종육종 치료제 시장 : 유형별
- 피부섬유육종의 시장 규모 및 예측 : 지역별
- 평활근육종의 시장 규모·예측 : 지역별
- 활막세포육종의 시장 규모·예측 : 지역별
- 횡문근육종의 시장 규모 및 예측 : 지역별
- 기타 시장 규모·예측 : 지역별
제5장 육종 치료제 시장 : 치료법별
- 개요
- 시장 규모·예측
- 화학요법
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
- 표적 약물요법
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
제6장 육종 치료제 시장 : 최종 사용자별
- 개요
- 시장 규모 및 예측
- 병원?진료소
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
- 암 연구 센터
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 분석 : 국가별
제7장 육종 치료제 시장 : 지역별
- 개요
- 시장 규모 및 예측
- 북미
- 주요 동향과 기회
- 북미 시장 규모·예측 : 질환 적응증별
- 북미 연부육종육종 치료제 시장 : 유형별
- 북미 연부육종 시장 규모·예측 : 치료법별
- 북미 연부육종 시장 규모·예측 : 엔드유저별
- 북미 연부 육종 시장 규모·예측 : 국가별
- 미국
- 캐나다
- 멕시코
- 유럽
- 주요 동향과 기회
- 유럽의 시장 규모·예측 : 적응증별
- 유럽 연부 육종의 육종 치료제 시장 : 유형별
- 유럽 연부 육종 시장 규모·예측 : 치료법별
- 유럽 연부 육종 시장 규모·예측 : 최종 사용자별
- 유럽 연부 육종 시장 규모·예측 : 국가별
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽 지역
- 아시아태평양
- 주요 동향과 기회
- 아시아태평양지역의 시장 규모·예측 : 적응질환별
- 아시아태평양의 연부 육종의 육종 치료제 시장 : 유형별
- 아시아태평양의 시장 규모·예측 : 치료법별
- 아시아태평양의 시장 규모·예측 : 최종 사용자별
- 아시아태평양 육종 시장 규모·예측 : 국가별
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- LAMEA
- 주요 동향과 기회
- LAMEA의 시장 규모·예측 : 질환적응증별
- LAMEA 연부육종육종 치료제 시장 : 유형별
- LAMEA 연부육종의 시장 규모·예측 : 치료법별
- LAMEA 연부육종 시장의 시장 규모·예측 : 최종 사용자별
- LAMEA의 시장 규모·예측 : 국가별
- 브라질
- 사우디아라비아
- 남아프리카 공화국
- 기타 LAMEA
제8장 기업 정세
- 소개
- 주요 성공 전략
- 주요 10개사의 제품 매핑
- 경쟁 대시보드
- 경합의 히트 맵
- 주요 발전
제9장 기업 프로필
- Baxter Healthcare Corporation
- BRISTOL-MYERS SQUIBB COMPANY
- Daiichi Sankyo Company, Limited
- AgonOX, Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline, plc.
- Hoffmann-La Roche AG.
- Johnson and Johnson
- MERCK & CO., INC.
- Novartis AG
The global sarcoma drugs market was valued at $1,127 million in 2021, and is projected to reach $2,497.1 million by 2031, growing at a CAGR of 8.3% from 2022 to 2031. Sarcoma is a form of cancer that develops in soft tissues such as cartilage, fat, muscle, blood vessels, fibrous tissue, and other connective or supportive tissues as well as in bone. Based on where the cancer develops, there are various varieties of sarcoma. For instance, rhabdomyosarcoma develops in muscles, liposarcoma develops in fat, and osteosarcoma develops in bones. The type and grade of the cancer determines course of treatment and prognosis (how abnormal the cancer cells look under a microscope and how quickly the cancer is likely to grow and spread). Both children and adults can develop sarcoma. Chemotherapy and targeted therapy are two treatment options available for sarcoma treatment.
The sarcoma drugs market is driven by rise in prevalence of cancer, technological advancements in development of sarcoma drugs, and rise in number of product launches and approvals for sarcoma drugs. For instance, according to the World Cancer Research Fund International, it was reported that 18,094,716 cancer cases were diagnosed across the globe. In addition, rise in prevalence of soft tissue sarcoma fuels demand for sarcoma drugs for treatment purpose. Thus, this factor is anticipated to drive growth of the sarcoma drugs market. For instance, according to the American Cancer Society, in 2022, it was estimated that about 13,190 new soft tissue sarcomas will be diagnosed, among them 7,590 in males and 5,600 in females in the U.S. in 2022. As per the same source, it was estimated that around 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas.
The global sarcoma drugs market is predicted to develop as more patients battle soft tissue sarcoma, which causes increase in shift of consumer preference toward medicinal treatment over surgical procedures. The use of chemotherapy and targeted therapy supported by a number of advantages, including quicker healing, lower morbidity and mortality, and shorter hospital stays.
Geriatric population is more susceptible to chronic diseases such as cancer. Rise in number of geriatric populations increases demand of sarcoma drugs for cancer treatment. Thus, this factor contributes toward growth of the sarcoma drugs market. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2019 to 2020, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019. Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment used at public health centers (hospitals). Hence, this rise in healthcare expenditure across the globe is expected to fuel demand for sarcoma drugs in different disease treatments, which boosts the market growth.
On the other hand, high cost associated with sarcoma drugs and side effects of chemotherapy hinder the market growth.
The global sarcoma drugs market is segmented on the basis of disease indication, treatment, end user, and region. On the basis of type the market is segmented into malignant bone tumors and soft tissue sarcoma. The soft tissue sarcoma segment is further sub-segmented into dermatofibrosarcoma, leiomyosarcoma, synovial cell sarcoma, rhabdomyosarcoma, and others. On the basis of treatment, the market is segmented into chemotherapy and targeted drug therapy. By end user, it is bifurcated into hospitals & clinics and cancer research centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global sarcoma drugs market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Hoffmann-La Roche AG., Daiichi Sankyo Company, Limited., AgonOX, Inc. and Eisai Co., Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sarcoma drugs market analysis from 2021 to 2031 to identify the prevailing sarcoma drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the sarcoma drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global sarcoma drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Indication
- Malignant bone tumors
- Soft tissue sarcoma
- Type
- Dermatofibro sarcoma
- Leiomyosarcoma
- Synovial cell sarcoma
- Rhabdomyo sarcoma
- Others
By Treatment
- Chemotherapy
- Targeted drug therapy
By End User
- Hospital and clinics
- Cancer research center
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Baxter Healthcare Corporation
- BRISTOL-MYERS SQUIBB COMPANY
- Daiichi Sankyo Company, Limited
- AgonOX, Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline, plc.
- Hoffmann-La Roche AG.
- Johnson and Johnson
- MERCK & CO., INC.
- Novartis AG
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: SARCOMA DRUGS MARKET, BY DISEASE INDICATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Malignant bone tumors
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Soft tissue sarcoma
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Soft tissue sarcoma Sarcoma Drugs Market by Type
- 4.3.4.1 Dermatofibro sarcoma Market size and forecast, by region
- 4.3.4.2 Leiomyosarcoma Market size and forecast, by region
- 4.3.4.3 Synovial cell sarcoma Market size and forecast, by region
- 4.3.4.4 Rhabdomyo sarcoma Market size and forecast, by region
- 4.3.4.5 Others Market size and forecast, by region
CHAPTER 5: SARCOMA DRUGS MARKET, BY TREATMENT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Targeted drug therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
CHAPTER 6: SARCOMA DRUGS MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital and clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Cancer research center
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
CHAPTER 7: SARCOMA DRUGS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Indication
- 7.2.2.1 North America Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Disease Indication
- 7.2.5.1.2 Market size and forecast, by Treatment
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Disease Indication
- 7.2.5.2.2 Market size and forecast, by Treatment
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Disease Indication
- 7.2.5.3.2 Market size and forecast, by Treatment
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Indication
- 7.3.2.1 Europe Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Disease Indication
- 7.3.5.1.2 Market size and forecast, by Treatment
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Disease Indication
- 7.3.5.2.2 Market size and forecast, by Treatment
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Disease Indication
- 7.3.5.3.2 Market size and forecast, by Treatment
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Disease Indication
- 7.3.5.4.2 Market size and forecast, by Treatment
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Disease Indication
- 7.3.5.5.2 Market size and forecast, by Treatment
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Disease Indication
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Indication
- 7.4.2.1 Asia-Pacific Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Disease Indication
- 7.4.5.1.2 Market size and forecast, by Treatment
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Disease Indication
- 7.4.5.2.2 Market size and forecast, by Treatment
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Disease Indication
- 7.4.5.3.2 Market size and forecast, by Treatment
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Disease Indication
- 7.4.5.4.2 Market size and forecast, by Treatment
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Disease Indication
- 7.4.5.5.2 Market size and forecast, by Treatment
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Disease Indication
- 7.4.5.6.2 Market size and forecast, by Treatment
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Indication
- 7.5.2.1 LAMEA Soft tissue sarcoma Sarcoma Drugs Market by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Disease Indication
- 7.5.5.1.2 Market size and forecast, by Treatment
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Disease Indication
- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Disease Indication
- 7.5.5.3.2 Market size and forecast, by Treatment
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Disease Indication
- 7.5.5.4.2 Market size and forecast, by Treatment
- 7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 Baxter Healthcare Corporation
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 BRISTOL-MYERS SQUIBB COMPANY
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Daiichi Sankyo Company, Limited
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 AgonOX, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eisai Co., Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 GlaxoSmithKline, plc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Hoffmann-La Roche AG.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Johnson and Johnson
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 MERCK & CO., INC.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
